Effect of Yishen Jiedu Tongluo capsule combined with losartan potassium on SphK1-S1P signaling pathway in patients with diabetic nephropathy

Abstract

Objective To study the clinical effect of combined therapy of Yishen Jiedu Tongluo capsule and losartan potassium in patients with diabetic nephropathy (DN). Methods A total of 104 patients with DN in our hospital from March 2016 to May 2018 were enrolled, and were divided into the observation group (n=52) and the control group (n=52) according to the random number table. The control group was treated with losartan potassium, and the observation group was treated with Yishen Jiedu Tongluo capsule and losartan potassium. The efficacy, adverse reactions, and sphingosine kinase 1 (Sphk1) activity, blood glucose levels [fasting blood glucose (FPG), postprandial 2h blood glucose (2hPG)], renal function [serum cystatin C (CysC) level, urinary albumin / creatinine (UACR) value] before treatment and after 3 courses of treatment of the two groups were compared. Results (1) Efficacy: the total effective rate of the observation group was 90.38% (47/52), which was higher than 75.00% (39/52) of the control group (P 0.05). (5) Renal function: after 3 courses of treatment, serum CysC level and UACR value were significantly improved in both two groups, and those in the observation group were lower than those in the control group (P<0.05). (6) Adverse reactions: no adverse reactions such as dizziness, nausea, rash, palpitation, etc. Conclusion The combination of Yishen Jiedu Tongluo capsule and losartan potassium is effective in the treatment of DN patients, which can effectively regulate the Sphk1-S1P pathway, improve clinical symptoms and renal function, with high safety. Key words: Diabetic nephropathy; Yishen Jiedu Tongluo capsule; Adverse reactions; Losartan potassium; Fasting blood glucose; Postprandial 2h blood glucose; Serum cystatin C; Sphk1-S1P pathway